基孔肯雅病毒 E2 蛋白的特定结构域调节人细胞中的颗粒形成：对甲病毒疫苗设计的影响。
A specific domain of the Chikungunya virus E2 protein regulates particle formation in human cells: implications for alphavirus vaccine design.
机构信息
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
出版信息
J Virol. 2012 Aug;86(16):8879-83. doi: 10.1128/JVI.00370-12. Epub 2012 May 30.
Abstract
Virus-like particles (VLPs) can be generated from Chikungunya virus (CHIKV), but different strains yield variable quantities of particles. Here, we define the genetic basis for these differences and show that amino acid 234 in E2 substantially affects VLP production. This site is located within the acid-sensitive region (ASR) known to initiate a major conformational change in E1/E2. Selected other mutations in the ASR, or changes in pH, also increased VLP yield. These results demonstrate that the ASR of E2 plays an important role in regulating particle generation.
摘要
病毒样颗粒（VLPs）可以从基孔肯雅病毒（CHIKV）中产生，但不同的毒株产生的颗粒数量不同。在这里，我们确定了这些差异的遗传基础，并表明 E2 中的氨基酸 234 会极大地影响 VLP 的产生。该位点位于酸敏感区（ASR）内，已知该区域会引发 E1/E2 中的主要构象变化。ASR 中的其他选定突变或 pH 变化也会增加 VLP 的产量。这些结果表明 E2 的 ASR 在调节颗粒生成中起着重要作用。
相似文献
1
A specific domain of the Chikungunya virus E2 protein regulates particle formation in human cells: implications for alphavirus vaccine design.基孔肯雅病毒 E2 蛋白的特定结构域调节人细胞中的颗粒形成：对甲病毒疫苗设计的影响。
J Virol. 2012 Aug;86(16):8879-83. doi: 10.1128/JVI.00370-12. Epub 2012 May 30.
2
Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits.与糖蛋白 E1 或 E2 亚单位相比，基孔肯雅病毒样颗粒在致死性 AG129 小鼠模型中具有更高的免疫原性。
Vaccine. 2013 Dec 9;31(51):6092-6. doi: 10.1016/j.vaccine.2013.09.045. Epub 2013 Oct 5.
3
Bacteriophage Qβ virus-like particles displaying Chikungunya virus B-cell epitopes elicit high-titer E2 protein antibodies but fail to neutralize a Thailand strain of Chikungunya virus.展示基孔肯雅病毒 B 细胞表位的噬菌体 Qβ 病毒样颗粒能诱导高滴度的 E2 蛋白抗体，但不能中和泰国基孔肯雅病毒株。
Vaccine. 2020 Mar 4;38(11):2542-2550. doi: 10.1016/j.vaccine.2020.01.091. Epub 2020 Feb 7.
4
Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice.二价嵌合病毒样颗粒和 DNA 疫苗共免疫诱导小鼠产生有前景的体液免疫应答。
Front Immunol. 2021 Mar 24;12:655743. doi: 10.3389/fimmu.2021.655743. eCollection 2021.
5
Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.抗基孔肯雅病毒单克隆抗体抑制病毒融合和释放。
J Virol. 2020 Sep 15;94(19). doi: 10.1128/JVI.00252-20.
6
Analysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated With a Candidate CHIKV Vaccine.分析感染基孔肯雅病毒（CHIKV）患者和接种候选 CHIKV 疫苗个体的体液免疫应答。
J Infect Dis. 2020 Apr 27;221(10):1713-1723. doi: 10.1093/infdis/jiz658.
7
Development and application of a reversed-phase high-performance liquid chromatographic method for quantitation and characterization of a Chikungunya virus-like particle vaccine.一种用于定量和表征基孔肯雅病毒样颗粒疫苗的反相高效液相色谱法的开发与应用
J Chromatogr A. 2014 Oct 17;1364:192-7. doi: 10.1016/j.chroma.2014.05.087. Epub 2014 Jun 19.
8
Production of Chikungunya Virus-Like Particles and Subunit Vaccines in Insect Cells.在昆虫细胞中生产基孔肯雅病毒样颗粒和亚单位疫苗。
Methods Mol Biol. 2016;1426:297-309. doi: 10.1007/978-1-4939-3618-2_27.
9
A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection.一种类似病毒的颗粒疫苗可预防基孔肯雅热病毒，保护非人灵长类动物免受感染。
Nat Med. 2010 Mar;16(3):334-8. doi: 10.1038/nm.2105. Epub 2010 Jan 28.
10
Attenuation of Chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein.基孔肯雅病毒疫苗株 181/克隆 25 的衰减由 E2 包膜糖蛋白中的两个氨基酸取代决定。
J Virol. 2012 Jun;86(11):6084-96. doi: 10.1128/JVI.06449-11. Epub 2012 Mar 28.
引用本文的文献
1
The alphavirus determinants of intercellular long extension formation.细胞间长延伸形成的甲病毒决定因素。
mBio. 2025 Feb 5;16(2):e0198624. doi: 10.1128/mbio.01986-24. Epub 2024 Dec 19.
2
Chikungunya virus vaccine: a decade of progress solving epidemiological dilemma, emerging concepts, and immunological interventions.基孔肯雅病毒疫苗：解决流行病学困境、新出现概念及免疫干预措施的十年进展
Front Microbiol. 2024 Jul 22;15:1413250. doi: 10.3389/fmicb.2024.1413250. eCollection 2024.
3
Antigenicity and immunogenicity of chikungunya virus-like particles from mosquito cells.蚊细胞来源的基孔肯雅病毒样颗粒的抗原性和免疫原性。
Appl Microbiol Biotechnol. 2023 Jan;107(1):219-232. doi: 10.1007/s00253-022-12280-8. Epub 2022 Nov 25.
4
Generation of a Live-Attenuated Strain of Chikungunya Virus from an Indian Isolate for Vaccine Development.从一株印度分离株产生用于疫苗开发的基孔肯雅病毒减毒活毒株。
Vaccines (Basel). 2022 Nov 16;10(11):1939. doi: 10.3390/vaccines10111939.
5
CHIKV strains Brazil (wt) and Ross (lab-adapted) differ with regard to cell host range and antiviral sensitivity and show CPE in human glioblastoma cell lines U138 and U251.基孔肯雅病毒（CHIKV）的巴西（野生型）毒株和罗斯（实验室适应型）毒株在细胞宿主范围和抗病毒敏感性方面存在差异，并且在人胶质母细胞瘤细胞系U138和U251中表现出细胞病变效应。
Virus Genes. 2022 Jun;58(3):188-202. doi: 10.1007/s11262-022-01892-x. Epub 2022 Mar 26.
6
Expression, Purification, and Refolding of Chikungunya Virus Full-Length Envelope E2 Protein along with B-Cell and T-Cell Epitope Analyses Using Immuno-Informatics Approaches.基孔肯雅病毒全长包膜E2蛋白的表达、纯化与复性以及利用免疫信息学方法进行B细胞和T细胞表位分析
ACS Omega. 2022 Jan 14;7(4):3491-3513. doi: 10.1021/acsomega.1c05975. eCollection 2022 Feb 1.
7
Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases.病毒样颗粒：用于开发针对新发传染病疫苗的革命性平台。
Front Microbiol. 2022 Jan 3;12:790121. doi: 10.3389/fmicb.2021.790121. eCollection 2021.
8
Insights into Antibody-Mediated Alphavirus Immunity and Vaccine Development Landscape.深入了解抗体介导的甲病毒免疫和疫苗开发前景。
Microorganisms. 2021 Apr 22;9(5):899. doi: 10.3390/microorganisms9050899.
9
Berberine Chloride is an Alphavirus Inhibitor That Targets Nucleocapsid Assembly.盐酸小檗碱是一种靶向核衣壳组装的甲病毒抑制剂。
mBio. 2020 Jun 30;11(3):e01382-20. doi: 10.1128/mBio.01382-20.
10
Comprehensive Flow Cytometry Analysis of PEI-Based Transfections for Virus-Like Particle Production.基于聚乙烯亚胺转染用于病毒样颗粒生产的综合流式细胞术分析
Research (Wash D C). 2020 Mar 13;2020:1387402. doi: 10.34133/2020/1387402. eCollection 2020.
本文引用的文献
1
Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography.X 射线晶体学揭示的基孔肯雅病毒粒子的糖蛋白组织。
Nature. 2010 Dec 2;468(7324):709-12. doi: 10.1038/nature09555.
2
Structural changes of envelope proteins during alphavirus fusion.包膜蛋白在甲病毒融合过程中的结构变化。
Nature. 2010 Dec 2;468(7324):705-8. doi: 10.1038/nature09546.
3
Host alternation of chikungunya virus increases fitness while restricting population diversity and adaptability to novel selective pressures.基孔肯雅热病毒的宿主转换会增加其适应性，同时限制种群多样性和对新选择压力的适应能力。
J Virol. 2011 Jan;85(2):1025-35. doi: 10.1128/JVI.01918-10. Epub 2010 Nov 3.
4
Chikungunya virus arthritis in adult wild-type mice.成人野生型小鼠中的基孔肯雅病毒关节炎。
J Virol. 2010 Aug;84(16):8021-32. doi: 10.1128/JVI.02603-09. Epub 2010 Jun 2.
5
A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection.一种类似病毒的颗粒疫苗可预防基孔肯雅热病毒，保护非人灵长类动物免受感染。
Nat Med. 2010 Mar;16(3):334-8. doi: 10.1038/nm.2105. Epub 2010 Jan 28.
6
Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity.通过具有改变的受体结合特异性的禽H5流感血凝素突变体进行免疫接种。
Science. 2007 Aug 10;317(5839):825-8. doi: 10.1126/science.1135165.
7
Virus-like particles: flexible platforms for vaccine development.病毒样颗粒：疫苗开发的灵活平台
Expert Rev Vaccines. 2007 Jun;6(3):381-90. doi: 10.1586/14760584.6.3.381.
8
The dynamic envelope of a fusion class II virus. Prefusion stages of semliki forest virus revealed by electron cryomicroscopy.II类融合病毒的动态包膜。电子冷冻显微镜揭示的Semliki森林病毒的融合前阶段。
J Biol Chem. 2007 Mar 2;282(9):6752-62. doi: 10.1074/jbc.M609125200. Epub 2006 Dec 27.
9
Association of sindbis virus capsid protein with phospholipid membranes and the E2 glycoprotein: implications for alphavirus assembly.辛德毕斯病毒衣壳蛋白与磷脂膜及E2糖蛋白的关联：对甲病毒装配的影响
Biochemistry. 2005 Mar 1;44(8):2800-10. doi: 10.1021/bi0479961.
10
Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines.多基因及分支的1型人类免疫缺陷病毒DNA疫苗的免疫原性
J Virol. 2003 Dec;77(23):12764-72. doi: 10.1128/jvi.77.23.12764-12772.2003.
Zotero 插件